BRIACELL THERAP (BCTX)
(Delayed Data from NSDQ)
$0.81 USD
-0.43 (-34.68%)
Updated Oct 1, 2024 04:00 PM ET
After-Market: $0.84 +0.03 (3.70%) 7:58 PM ET
1-Strong Buy of 5 1
F Value D Growth B Momentum F VGM
Price, Consensus and EPS Surprise
BCTX 0.81 -0.43(-34.68%)
Will BCTX be a Portfolio Killer in October?
Zacks Investment Research is releasing its prediction for BCTX based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for BCTX
What Makes BRIACELL THERAP (BCTX) a New Strong Buy Stock
BCTX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for BCTX
BriaCell dips despite promising mid-stage data for breast cancer therapy
BriaCell Achieves Breakthrough in Breast Cancer Treatment
BriaCell reports anti-tumor response in patient treated in Phase 2 study
BriaCell Therapeutics Launches $5 Million Offering
BriaCell Announces FDA-Authorized Expanded Access Policy for Metastatic Breast Cancer Patients